Unipath Ltd.
Industry
- Biotechnology
- In Vitro Diagnostics
See more in Biomedtracker
Latest on Unipath Ltd.
In Vivo
In the past two years, Inverness Medical Innovations has paid roughly a combined $500 million to buy five rapid point-of-care (POCT) diagnostic testing businesses, which now lie at the heart of its
In Vivo
A look at financing, M&A, and alliance activity in October-December 2001 In this issue we are presenting another installment of our quarterly review of dealmaking—in this case October to December 2001
Medtech Insight
Fertility Diagnostics for Home Use The current screen for infertility is quite simply to try to conceive over a period of 12 months. Only then, if there is still no pregnancy, are couples eligible for